Record Information |
---|
Version | 5.0 |
---|
Status | Detected but not Quantified |
---|
Creation Date | 2021-09-11 00:43:36 UTC |
---|
Update Date | 2021-09-26 22:57:30 UTC |
---|
HMDB ID | HMDB0247670 |
---|
Secondary Accession Numbers | None |
---|
Metabolite Identification |
---|
Common Name | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol |
---|
Description | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol belongs to the class of organic compounds known as imidazo-[4,5-c]pyridines. These are organic heterocyclic compounds containing an imidazo-[4,5-c]pyridine ring system. Imidazo-[4,5-c]pyridine consists of an imidazole ring fused to a pyridine, so that the three ring nitrogen atoms are at the 1-, 2-, and 5-position, respectively. Based on a literature review very few articles have been published on (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol. This compound has been identified in human blood as reported by (PMID: 31557052 ). (s)-4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1h-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
---|
Structure | CCN1C(=NC2=C1C(OCC1CCCNC1)=CN=C2C#CC(C)(C)O)C1=NON=C1N InChI=1S/C21H27N7O3/c1-4-28-18-15(30-12-13-6-5-9-23-10-13)11-24-14(7-8-21(2,3)29)16(18)25-20(28)17-19(22)27-31-26-17/h11,13,23,29H,4-6,9-10,12H2,1-3H3,(H2,22,27) |
---|
Synonyms | Not Available |
---|
Chemical Formula | C21H27N7O3 |
---|
Average Molecular Weight | 425.493 |
---|
Monoisotopic Molecular Weight | 425.217537757 |
---|
IUPAC Name | 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(piperidin-3-yl)methoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methylbut-3-yn-2-ol |
---|
Traditional Name | 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)imidazo[4,5-c]pyridin-4-yl]-2-methylbut-3-yn-2-ol |
---|
CAS Registry Number | Not Available |
---|
SMILES | CCN1C(=NC2=C1C(OCC1CCCNC1)=CN=C2C#CC(C)(C)O)C1=NON=C1N |
---|
InChI Identifier | InChI=1S/C21H27N7O3/c1-4-28-18-15(30-12-13-6-5-9-23-10-13)11-24-14(7-8-21(2,3)29)16(18)25-20(28)17-19(22)27-31-26-17/h11,13,23,29H,4-6,9-10,12H2,1-3H3,(H2,22,27) |
---|
InChI Key | KGPGFQWBCSZGEL-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as imidazo-[4,5-c]pyridines. These are organic heterocyclic compounds containing an imidazo-[4,5-c]pyridine ring system. Imidazo-[4,5-c]pyridine consists of an imidazole ring fused to a pyridine, so that the three ring nitrogen atoms are at the 1-, 2-, and 5-position, respectively. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Imidazopyridines |
---|
Sub Class | Imidazo-[4,5-c]pyridines |
---|
Direct Parent | Imidazo-[4,5-c]pyridines |
---|
Alternative Parents | |
---|
Substituents | - Imidazo-[4,5-c]pyridine
- Alkyl aryl ether
- N-substituted imidazole
- Piperidine
- Pyridine
- Ynone
- Imidolactam
- Heteroaromatic compound
- Tertiary alcohol
- Azole
- Oxadiazole
- Furazan
- Imidazole
- Azacycle
- Secondary amine
- Secondary aliphatic amine
- Ether
- Organopnictogen compound
- Alcohol
- Organonitrogen compound
- Organooxygen compound
- Organic nitrogen compound
- Primary amine
- Amine
- Organic oxygen compound
- Hydrocarbon derivative
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Not Available |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
(S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,2TMS,isomer #1 | CCN1C(C2=NON=C2N[Si](C)(C)C)=NC2=C(C#CC(C)(C)O[Si](C)(C)C)N=CC(OCC3CCCNC3)=C21 | 3567.4 | Semi standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,2TMS,isomer #1 | CCN1C(C2=NON=C2N[Si](C)(C)C)=NC2=C(C#CC(C)(C)O[Si](C)(C)C)N=CC(OCC3CCCNC3)=C21 | 3620.4 | Standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,2TMS,isomer #1 | CCN1C(C2=NON=C2N[Si](C)(C)C)=NC2=C(C#CC(C)(C)O[Si](C)(C)C)N=CC(OCC3CCCNC3)=C21 | 5512.0 | Standard polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,2TMS,isomer #2 | CCN1C(C2=NON=C2N)=NC2=C(C#CC(C)(C)O[Si](C)(C)C)N=CC(OCC3CCCN([Si](C)(C)C)C3)=C21 | 3623.1 | Semi standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,2TMS,isomer #2 | CCN1C(C2=NON=C2N)=NC2=C(C#CC(C)(C)O[Si](C)(C)C)N=CC(OCC3CCCN([Si](C)(C)C)C3)=C21 | 3492.2 | Standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,2TMS,isomer #2 | CCN1C(C2=NON=C2N)=NC2=C(C#CC(C)(C)O[Si](C)(C)C)N=CC(OCC3CCCN([Si](C)(C)C)C3)=C21 | 5739.6 | Standard polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,2TMS,isomer #3 | CCN1C(C2=NON=C2N([Si](C)(C)C)[Si](C)(C)C)=NC2=C(C#CC(C)(C)O)N=CC(OCC3CCCNC3)=C21 | 3508.2 | Semi standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,2TMS,isomer #3 | CCN1C(C2=NON=C2N([Si](C)(C)C)[Si](C)(C)C)=NC2=C(C#CC(C)(C)O)N=CC(OCC3CCCNC3)=C21 | 3709.2 | Standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,2TMS,isomer #3 | CCN1C(C2=NON=C2N([Si](C)(C)C)[Si](C)(C)C)=NC2=C(C#CC(C)(C)O)N=CC(OCC3CCCNC3)=C21 | 5212.8 | Standard polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,2TMS,isomer #4 | CCN1C(C2=NON=C2N[Si](C)(C)C)=NC2=C(C#CC(C)(C)O)N=CC(OCC3CCCN([Si](C)(C)C)C3)=C21 | 3657.6 | Semi standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,2TMS,isomer #4 | CCN1C(C2=NON=C2N[Si](C)(C)C)=NC2=C(C#CC(C)(C)O)N=CC(OCC3CCCN([Si](C)(C)C)C3)=C21 | 3570.5 | Standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,2TMS,isomer #4 | CCN1C(C2=NON=C2N[Si](C)(C)C)=NC2=C(C#CC(C)(C)O)N=CC(OCC3CCCN([Si](C)(C)C)C3)=C21 | 5639.3 | Standard polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,3TMS,isomer #1 | CCN1C(C2=NON=C2N([Si](C)(C)C)[Si](C)(C)C)=NC2=C(C#CC(C)(C)O[Si](C)(C)C)N=CC(OCC3CCCNC3)=C21 | 3554.3 | Semi standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,3TMS,isomer #1 | CCN1C(C2=NON=C2N([Si](C)(C)C)[Si](C)(C)C)=NC2=C(C#CC(C)(C)O[Si](C)(C)C)N=CC(OCC3CCCNC3)=C21 | 3692.5 | Standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,3TMS,isomer #1 | CCN1C(C2=NON=C2N([Si](C)(C)C)[Si](C)(C)C)=NC2=C(C#CC(C)(C)O[Si](C)(C)C)N=CC(OCC3CCCNC3)=C21 | 4837.8 | Standard polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,3TMS,isomer #2 | CCN1C(C2=NON=C2N[Si](C)(C)C)=NC2=C(C#CC(C)(C)O[Si](C)(C)C)N=CC(OCC3CCCN([Si](C)(C)C)C3)=C21 | 3669.4 | Semi standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,3TMS,isomer #2 | CCN1C(C2=NON=C2N[Si](C)(C)C)=NC2=C(C#CC(C)(C)O[Si](C)(C)C)N=CC(OCC3CCCN([Si](C)(C)C)C3)=C21 | 3562.2 | Standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,3TMS,isomer #2 | CCN1C(C2=NON=C2N[Si](C)(C)C)=NC2=C(C#CC(C)(C)O[Si](C)(C)C)N=CC(OCC3CCCN([Si](C)(C)C)C3)=C21 | 5320.1 | Standard polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,3TMS,isomer #3 | CCN1C(C2=NON=C2N([Si](C)(C)C)[Si](C)(C)C)=NC2=C(C#CC(C)(C)O)N=CC(OCC3CCCN([Si](C)(C)C)C3)=C21 | 3613.1 | Semi standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,3TMS,isomer #3 | CCN1C(C2=NON=C2N([Si](C)(C)C)[Si](C)(C)C)=NC2=C(C#CC(C)(C)O)N=CC(OCC3CCCN([Si](C)(C)C)C3)=C21 | 3701.6 | Standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,3TMS,isomer #3 | CCN1C(C2=NON=C2N([Si](C)(C)C)[Si](C)(C)C)=NC2=C(C#CC(C)(C)O)N=CC(OCC3CCCN([Si](C)(C)C)C3)=C21 | 4997.3 | Standard polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,4TMS,isomer #1 | CCN1C(C2=NON=C2N([Si](C)(C)C)[Si](C)(C)C)=NC2=C(C#CC(C)(C)O[Si](C)(C)C)N=CC(OCC3CCCN([Si](C)(C)C)C3)=C21 | 3666.5 | Semi standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,4TMS,isomer #1 | CCN1C(C2=NON=C2N([Si](C)(C)C)[Si](C)(C)C)=NC2=C(C#CC(C)(C)O[Si](C)(C)C)N=CC(OCC3CCCN([Si](C)(C)C)C3)=C21 | 3681.7 | Standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,4TMS,isomer #1 | CCN1C(C2=NON=C2N([Si](C)(C)C)[Si](C)(C)C)=NC2=C(C#CC(C)(C)O[Si](C)(C)C)N=CC(OCC3CCCN([Si](C)(C)C)C3)=C21 | 4696.7 | Standard polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,2TBDMS,isomer #1 | CCN1C(C2=NON=C2N[Si](C)(C)C(C)(C)C)=NC2=C(C#CC(C)(C)O[Si](C)(C)C(C)(C)C)N=CC(OCC3CCCNC3)=C21 | 3862.5 | Semi standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,2TBDMS,isomer #1 | CCN1C(C2=NON=C2N[Si](C)(C)C(C)(C)C)=NC2=C(C#CC(C)(C)O[Si](C)(C)C(C)(C)C)N=CC(OCC3CCCNC3)=C21 | 3952.2 | Standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,2TBDMS,isomer #1 | CCN1C(C2=NON=C2N[Si](C)(C)C(C)(C)C)=NC2=C(C#CC(C)(C)O[Si](C)(C)C(C)(C)C)N=CC(OCC3CCCNC3)=C21 | 5430.4 | Standard polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,2TBDMS,isomer #2 | CCN1C(C2=NON=C2N)=NC2=C(C#CC(C)(C)O[Si](C)(C)C(C)(C)C)N=CC(OCC3CCCN([Si](C)(C)C(C)(C)C)C3)=C21 | 3969.6 | Semi standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,2TBDMS,isomer #2 | CCN1C(C2=NON=C2N)=NC2=C(C#CC(C)(C)O[Si](C)(C)C(C)(C)C)N=CC(OCC3CCCN([Si](C)(C)C(C)(C)C)C3)=C21 | 3852.9 | Standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,2TBDMS,isomer #2 | CCN1C(C2=NON=C2N)=NC2=C(C#CC(C)(C)O[Si](C)(C)C(C)(C)C)N=CC(OCC3CCCN([Si](C)(C)C(C)(C)C)C3)=C21 | 5688.8 | Standard polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,2TBDMS,isomer #3 | CCN1C(C2=NON=C2N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=C(C#CC(C)(C)O)N=CC(OCC3CCCNC3)=C21 | 3845.5 | Semi standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,2TBDMS,isomer #3 | CCN1C(C2=NON=C2N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=C(C#CC(C)(C)O)N=CC(OCC3CCCNC3)=C21 | 4030.4 | Standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,2TBDMS,isomer #3 | CCN1C(C2=NON=C2N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=C(C#CC(C)(C)O)N=CC(OCC3CCCNC3)=C21 | 5153.8 | Standard polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,2TBDMS,isomer #4 | CCN1C(C2=NON=C2N[Si](C)(C)C(C)(C)C)=NC2=C(C#CC(C)(C)O)N=CC(OCC3CCCN([Si](C)(C)C(C)(C)C)C3)=C21 | 3982.8 | Semi standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,2TBDMS,isomer #4 | CCN1C(C2=NON=C2N[Si](C)(C)C(C)(C)C)=NC2=C(C#CC(C)(C)O)N=CC(OCC3CCCN([Si](C)(C)C(C)(C)C)C3)=C21 | 3931.4 | Standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,2TBDMS,isomer #4 | CCN1C(C2=NON=C2N[Si](C)(C)C(C)(C)C)=NC2=C(C#CC(C)(C)O)N=CC(OCC3CCCN([Si](C)(C)C(C)(C)C)C3)=C21 | 5652.7 | Standard polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,3TBDMS,isomer #1 | CCN1C(C2=NON=C2N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=C(C#CC(C)(C)O[Si](C)(C)C(C)(C)C)N=CC(OCC3CCCNC3)=C21 | 4012.5 | Semi standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,3TBDMS,isomer #1 | CCN1C(C2=NON=C2N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=C(C#CC(C)(C)O[Si](C)(C)C(C)(C)C)N=CC(OCC3CCCNC3)=C21 | 4167.4 | Standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,3TBDMS,isomer #1 | CCN1C(C2=NON=C2N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=C(C#CC(C)(C)O[Si](C)(C)C(C)(C)C)N=CC(OCC3CCCNC3)=C21 | 4826.0 | Standard polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,3TBDMS,isomer #2 | CCN1C(C2=NON=C2N[Si](C)(C)C(C)(C)C)=NC2=C(C#CC(C)(C)O[Si](C)(C)C(C)(C)C)N=CC(OCC3CCCN([Si](C)(C)C(C)(C)C)C3)=C21 | 4140.0 | Semi standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,3TBDMS,isomer #2 | CCN1C(C2=NON=C2N[Si](C)(C)C(C)(C)C)=NC2=C(C#CC(C)(C)O[Si](C)(C)C(C)(C)C)N=CC(OCC3CCCN([Si](C)(C)C(C)(C)C)C3)=C21 | 4089.3 | Standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,3TBDMS,isomer #2 | CCN1C(C2=NON=C2N[Si](C)(C)C(C)(C)C)=NC2=C(C#CC(C)(C)O[Si](C)(C)C(C)(C)C)N=CC(OCC3CCCN([Si](C)(C)C(C)(C)C)C3)=C21 | 5318.7 | Standard polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,3TBDMS,isomer #3 | CCN1C(C2=NON=C2N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=C(C#CC(C)(C)O)N=CC(OCC3CCCN([Si](C)(C)C(C)(C)C)C3)=C21 | 4115.9 | Semi standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,3TBDMS,isomer #3 | CCN1C(C2=NON=C2N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=C(C#CC(C)(C)O)N=CC(OCC3CCCN([Si](C)(C)C(C)(C)C)C3)=C21 | 4203.9 | Standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,3TBDMS,isomer #3 | CCN1C(C2=NON=C2N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=C(C#CC(C)(C)O)N=CC(OCC3CCCN([Si](C)(C)C(C)(C)C)C3)=C21 | 5038.1 | Standard polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,4TBDMS,isomer #1 | CCN1C(C2=NON=C2N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=C(C#CC(C)(C)O[Si](C)(C)C(C)(C)C)N=CC(OCC3CCCN([Si](C)(C)C(C)(C)C)C3)=C21 | 4271.0 | Semi standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,4TBDMS,isomer #1 | CCN1C(C2=NON=C2N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=C(C#CC(C)(C)O[Si](C)(C)C(C)(C)C)N=CC(OCC3CCCN([Si](C)(C)C(C)(C)C)C3)=C21 | 4320.5 | Standard non polar | 33892256 | (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol,4TBDMS,isomer #1 | CCN1C(C2=NON=C2N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=C(C#CC(C)(C)O[Si](C)(C)C(C)(C)C)N=CC(OCC3CCCN([Si](C)(C)C(C)(C)C)C3)=C21 | 4815.1 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol GC-MS (Non-derivatized) - 70eV, Positive | splash10-0r01-5009400000-f264885299ec4a5fb538 | 2021-09-24 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol GC-MS (TMS_1_1) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol GC-MS (TMS_1_2) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol GC-MS (TMS_1_3) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol GC-MS (TBDMS_1_2) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol GC-MS (TBDMS_1_3) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol 10V, Positive-QTOF | splash10-056r-0000900000-7e433c5c54e142ee15ad | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol 20V, Positive-QTOF | splash10-004i-0002900000-c6b4745fa748b2fa8b00 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol 40V, Positive-QTOF | splash10-0a4i-9015000000-c630725290830fb5295d | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol 10V, Negative-QTOF | splash10-00di-1000900000-22b1ce818837c0d83aa4 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol 20V, Negative-QTOF | splash10-006t-0019300000-d5dd0848fbdf0b24d815 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol 40V, Negative-QTOF | splash10-06r2-1389000000-9d8abb9c51fa59d4485f | 2021-10-12 | Wishart Lab | View Spectrum |
|
---|